About Oregon Bud Company Recreational Marijuana Dispensary Keizer

According to new studies, cannabis may be a successful treatment for people who have been diagnosed with multiple sclerosis. While it was once thought that the symptomatic changes experienced by cannabinoid-administered patients with multiple sclerosis were largely due to psychological causes, later studies revealed that cannabis actually decreases the muscle spasms and stiffness common in MS patients. Medical trials conducted over the short and long term demonstrated the positive effects of cannabis on patients with multiple sclerosis.You may find more details about this at Oregon Bud Company Recreational Marijuana Dispensary Keizer-Dispensary Near Me.

A team of researchers from the Peninsula Medical School in Exeter, UK, published the results of a series of short- and long-term studies on the effects of cannabinoids in patients with multiple sclerosis in 2003. Approximately 600 patients with advanced-stage multiple sclerosis were actively involved in previous research. Over a 15-week duration, the participants were split into two groups: the first received cannabinoid compounds in equal doses, while the second received placebo medicines. The majority of patients who were given cannabinoids had substantial symptomatic improvements, less muscle pain, and milder muscle spasticity by the end of the study (less pronounced muscle spasm). The control group (patients receiving placebo medication) did not experience any changes in their overall health, in comparison to the group that received cannabinoid compounds during the study period.

The research was later replicated to ensure the validity of the findings and to dispel any doubts regarding the effectiveness of cannabis in treating multiple sclerosis symptoms. The following research, which took place over a 12-month period and included the same subjects, was conducted. However, instead of two distinct groups, as in the previous experiment, this time the participants were split into three distinct groups. The first group received D9-tetrahydrocannabinol (THC) tablets, which are the active ingredient in cannabis, while the second and third groups received natural cannabis extracts and a placebo.

A team of physiotherapists and neurologists assessed and tested the patients at the conclusion of the study. The best results were obtained among the patients in the first sample group, with the majority of participants receiving equivalent doses of THC reporting substantial changes in their symptoms. Patients in the second group of the study had minor changes in their symptoms, while those in the third group had no difference in their condition.

Despite the fact that these findings clearly show that cannabis is an effective therapy for multiple sclerosis, medical scientists are still sceptical about the use of cannabinoids in MS treatment. Nonetheless, doctors will be able to prescribe the use of cannabinoid compounds in the treatment of multiple sclerosis in the near future after conducting additional research and studies on the topic.